丽珠集团：拟收购越南上市公司Imexpharm目前经营稳健

Core Viewpoint - The company is actively pursuing the acquisition of the Vietnamese listed company Imexpharm, which is currently operating steadily and has a high degree of product synergy with the company [1] Group 1: Acquisition and Business Operations - The acquisition of Imexpharm is expected to enhance the company's operational capabilities and market presence in Vietnam [1] - The company has established close communication with Imexpharm and is planning for future business collaboration [1] Group 2: Market Entry Challenges - The main challenges for the company's existing products entering the Vietnamese market include uncertainties in drug registration and production quality certification processes [1] - The company aims to leverage Imexpharm's established market channels and EU GMP certification advantages to systematically advance market expansion through product line complementarity and localized operational strategies [1]